Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the European Commission approved the company’s new cystic fibrosis treatment, ...

MADISON, Miss., March 04, 2022 (GLOBE NEWSWIRE) -- Vertex Aerospace today announces that going forward, it will be known as “The Vertex Company”. The announcement follows a successful ...

Vertex Pharmaceuticals' non-opioid painkiller significantly decreased pain in patients with diabetes suffering from chronic nerve pain in a mid-stage trial, fueling efforts to develop a treatment ...

Vertex reported revenues of $2.77 billion in the last reported quarter, representing a year-over-year change of +3%. EPS of $4.06 for the same period compares with $4.76 a year ago.

Vertex Pharmaceuticals on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected sales of its drugs for cystic fibrosis, and little or no contributions from a gene ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial ...

Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 ...

Vertex's stem cell therapy for type 1 diabetes allowed two patients to stop taking insulin, but experts caution more data are needed. Skip to Main Content. Mental Health. rare diseases.

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...